{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:58:59Z","timestamp":1792432739742,"version":"4.5.0"},"reference-count":56,"publisher":"Impact Journals, LLC","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,4,18]]},"DOI":"10.18632\/oncotarget.15410","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T16:33:37Z","timestamp":1487781217000},"page":"26169-26184","source":"Crossref","is-referenced-by-count":25,"title":["Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer"],"prefix":"10.18632","volume":"8","author":[{"given":"Helga","family":"Weber","sequence":"first","affiliation":[{"name":"Center of Excellence in Traslational Medicine (CEMT) and Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile"},{"name":"Department of Pathology, Faculty of Medicine, Temuco, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Valbuena","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa A.","family":"Barbhuiya","sequence":"additional","affiliation":[{"name":"McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Stein","sequence":"additional","affiliation":[{"name":"Gene Therapy Unit, Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Kunkel","sequence":"additional","affiliation":[{"name":"Gene Therapy Unit, Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Center for Investigation in Translational Oncology (CITO), Advanced Center for Chronic Diseases (ACCDiS), Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Bizama","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Center for Investigation in Translational Oncology (CITO), Advanced Center for Chronic Diseases (ACCDiS), Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Riquelme","sequence":"additional","affiliation":[{"name":"Center of Excellence in Traslational Medicine (CEMT) and Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile"},{"name":"Department of Pathology, Faculty of Medicine, Temuco, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime A.","family":"Espinoza","sequence":"additional","affiliation":[{"name":"SciLifeLab, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Kurtz","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Francisco","family":"Calderon","sequence":"additional","affiliation":[{"name":"Center for Genetics and Genomics, School of Medicine, Cl\u00ednica Alemana de Santiago - Universidad del Desarrollo, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro H.","family":"Corval\u00e1n","sequence":"additional","affiliation":[{"name":"Center for Investigation in Translational Oncology (CITO), Advanced Center for Chronic Diseases (ACCDiS), Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Department of Hematology Oncology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Grez","sequence":"additional","affiliation":[{"name":"Gene Therapy Unit, Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Pandey","sequence":"additional","affiliation":[{"name":"McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA"},{"name":"Department of Biological Chemistry, Department of Oncology, Department of Pathology, The Johns Hopkins University School of Medicine Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Leal-Rojas","sequence":"additional","affiliation":[{"name":"Center of Excellence in Traslational Medicine (CEMT) and Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Roa","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Center for Investigation in Translational Oncology (CITO), Advanced Center for Chronic Diseases (ACCDiS), Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,2,16]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrc1429","article-title":"Gallbladder cancer: lessons from a rare tumour","volume":"4","author":"Gazdar","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ctrv.2015.01.003","article-title":"Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy","volume":"41","author":"Roa","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1634\/theoncologist.2009-0302","article-title":"Current management of gallbladder carcinoma","volume":"15","author":"Kooby","year":"2010","journal-title":"Oncologist"},{"key":"4","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Ross","year":"2015","journal-title":"Lancet Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/0008-5472.CAN-12-1906","article-title":"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening","volume":"73","author":"Oh","year":"2013","journal-title":"Cancer Res"},{"key":"6","doi-asserted-by":"publisher","first-page":"18921","DOI":"10.18632\/oncotarget.4214","article-title":"Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma","volume":"6","author":"Tyner","year":"2015","journal-title":"Oncotarget"},{"key":"7","first-page":"277","article-title":"Hsp90 inhibitors as selective anticancer drugs","volume":"4","author":"Burrows","year":"2004","journal-title":"Discov Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Neckers","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"9","first-page":"2031","article-title":"Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer","volume":"29","author":"Stoeltzing","year":"2009","journal-title":"Anticancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00432-014-1896-8","article-title":"Inhibition of heat shock protein 90 suppresses squamous carcinogenic progression in a mouse model of esophageal cancer","volume":"141","author":"Zhong","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"11","doi-asserted-by":"crossref","first-page":"e1595","DOI":"10.1038\/cddis.2014.555","article-title":"Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer","volume":"6","author":"Tu","year":"2015","journal-title":"Cell Death Dis"},{"key":"12","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bbamcr.2011.10.008","article-title":"Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers","volume":"1823","author":"Chiosis","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"13","first-page":"1","article-title":"HSP90 inhibitors: current development and potential in cancer therapy","volume":"9","author":"Patsavoudi","year":"2014","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"14","first-page":"48","article-title":"Heat shock protein 90 targeting therapy: state of the art and future perspective","volume":"14","author":"Kihara","year":"2015","journal-title":"EXCLI J"},{"key":"15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10549-015-3355-x","article-title":"Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer","volume":"150","author":"Vandenberg","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"16","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/annonc\/mdm545","article-title":"HSP90 as a marker of progression in melanoma","volume":"19","author":"Kluger","year":"2008","journal-title":"Ann Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/CAD.0000000000000135","article-title":"Heat shock protein 90 inhibitor mycoepoxydiene modulates kinase signaling in cervical cancer cells and inhibits in-vivo tumor growth","volume":"26","author":"Zhang","year":"2015","journal-title":"Anticancer Drugs"},{"key":"18","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.tcb.2012.08.006","article-title":"A prescription for \u2018stress\u2019\u2014the role of Hsp90 in genome stability and cellular adaptation","volume":"22","author":"Li","year":"2012","journal-title":"Trends Cell Biol"},{"key":"19","doi-asserted-by":"crossref","first-page":"7125","DOI":"10.1158\/0008-5472.CAN-14-1017","article-title":"HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization","volume":"74","author":"Seufferlein","year":"2014","journal-title":"Cancer Res"},{"key":"20","first-page":"412985","article-title":"Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls","volume":"2010","author":"Isaacs","year":"2010","journal-title":"J Oncol"},{"key":"21","first-page":"271","article-title":"Effects of HSP90 inhibitor 17-AAG on cell cycle and apoptosis of human gastric cancer cell lines SGC-7901. [Article in Chinese]","volume":"33","author":"Zhao","year":"2013","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3892\/or.2013.2899","article-title":"The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt\/XIAP pathway","volume":"31","author":"Yasuda","year":"2014","journal-title":"Oncol Rep"},{"key":"23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","article-title":"Hsp90 molecular chaperone inhibitors: are we there yet?","volume":"18","author":"Workman","year":"2012","journal-title":"Clin Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s10637-015-0246-2","article-title":"Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study","volume":"33","author":"McWilliams","year":"2015","journal-title":"Invest New Drugs"},{"key":"25","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1158\/1078-0432.CCR-11-0072","article-title":"HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab","volume":"17","author":"Norton","year":"2011","journal-title":"Clin Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature01913","article-title":"A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors","volume":"425","author":"Burrows","year":"2003","journal-title":"Nature"},{"key":"27","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3390\/ph5091008","article-title":"Heat shock protein 90 (hsp90) expression and breast cancer","volume":"5","author":"Papadimitriou","year":"2012","journal-title":"Pharmaceuticals (Basel)"},{"key":"28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10238-012-0208-3","article-title":"The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells","volume":"13","author":"Yang","year":"2013","journal-title":"Clin Exp Med"},{"key":"29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00280-008-0888-2","article-title":"Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2\/M cell cycle arrest and apoptosis","volume":"64","author":"Kim","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"30","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.18632\/oncotarget.1419","article-title":"Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX","volume":"4","author":"Workman","year":"2013","journal-title":"Oncotarget"},{"key":"31","doi-asserted-by":"crossref","first-page":"e71135","DOI":"10.1371\/journal.pone.0071135","article-title":"Geldanamycin-induced osteosarcoma cell death is associated with hyperacetylation and loss of mitochondrial pool of heat shock protein 60 (hsp60)","volume":"8","author":"Wakabayashi","year":"2013","journal-title":"PLoS One"},{"key":"32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1379\/CSC-254R.1","article-title":"Characterizing the role of Hsp90 in production of heat shock proteins in motor neurons reveals a suppressive effect of wild-type Hsf1","volume":"12","author":"Durham","year":"2007","journal-title":"Cell Stress Chaperones"},{"key":"33","doi-asserted-by":"crossref","first-page":"33097","DOI":"10.1074\/jbc.R500010200","article-title":"Heat shock response modulators as therapeutic tools for diseases of protein conformation","volume":"280","author":"Morimoto","year":"2005","journal-title":"J Biol Chem"},{"key":"34","first-page":"3312","article-title":"Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents","volume":"6","author":"Whitesell","year":"2000","journal-title":"Clin Cancer Res"},{"key":"35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/713803536","article-title":"Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells","volume":"48","author":"Kim","year":"1999","journal-title":"IUBMB life"},{"key":"36","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/1535-7163.MCT-08-0327","article-title":"Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines","volume":"7","author":"Martinez-Delgado","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"37","doi-asserted-by":"crossref","first-page":"45791","DOI":"10.1074\/jbc.M105931200","article-title":"Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex","volume":"276","author":"Voellmy","year":"2001","journal-title":"J Biol Chem"},{"key":"38","first-page":"1544","article-title":"Expression of Hsp90alpha and cyclin B1 were related to prognosis of esophageal squamous cell carcinoma and keratin pearl formation","volume":"7","author":"Chen","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Salomon","year":"2006","journal-title":"Gene"},{"key":"40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1186\/1471-2407-10-631","article-title":"Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas","volume":"10","author":"Leone","year":"2010","journal-title":"BMC cancer"},{"key":"41","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.virol.2007.09.003","article-title":"PI3K\/AKT inhibition induces caspase-dependent apoptosis in HTLV-1-transformed cells","volume":"370","author":"Brady","year":"2008","journal-title":"Virology"},{"key":"42","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/JTO.0b013e3181839693","article-title":"Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma","volume":"3","author":"Jablons","year":"2008","journal-title":"J Thorac Oncol"},{"key":"43","first-page":"551","article-title":"Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt\/MAPK\/Wnt pathways","volume":"34","author":"Freeman","year":"2009","journal-title":"Int J Oncol"},{"key":"44","doi-asserted-by":"crossref","first-page":"552","DOI":"10.5858\/arpa.2012-0032-OA","article-title":"Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma","volume":"137","author":"Roa","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"45","first-page":"1373","article-title":"AKT\/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines","volume":"6","author":"Roa","year":"2013","journal-title":"Onco Targets Ther"},{"key":"46","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/sj.onc.1207515","article-title":"Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks","volume":"23","author":"Kohn","year":"2004","journal-title":"Oncogene"},{"key":"47","doi-asserted-by":"crossref","first-page":"10832","DOI":"10.1073\/pnas.170276797","article-title":"Modulation of Akt kinase activity by binding to Hsp90","volume":"97","author":"Tsuruo","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"48","first-page":"2139","article-title":"Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol","volume":"63","author":"Rosen","year":"2003","journal-title":"Cancer Res"},{"key":"49","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1349-7006.2005.00125.x","article-title":"Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis","volume":"96","author":"Kubota","year":"2005","journal-title":"Cancer Sci"},{"key":"50","doi-asserted-by":"crossref","first-page":"52572","DOI":"10.1074\/jbc.M309054200","article-title":"Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress","volume":"278","author":"Karnitz","year":"2003","journal-title":"J Biol Chem"},{"key":"51","doi-asserted-by":"publisher","first-page":"31877","DOI":"10.18632\/oncotarget.5047","article-title":"Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice","volume":"6","author":"Roa","year":"2015","journal-title":"Oncotarget"},{"key":"52","doi-asserted-by":"crossref","first-page":"e77400","DOI":"10.1371\/journal.pone.0077400","article-title":"Combination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00280-004-0865-3","article-title":"Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts","volume":"55","author":"Egorin","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"54","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1200\/JCO.2009.25.0415","article-title":"Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors","volume":"28","author":"Belani","year":"2010","journal-title":"J Clin Oncol"},{"key":"55","doi-asserted-by":"crossref","first-page":"R56","DOI":"10.1186\/bcr2615","article-title":"ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67","volume":"12","author":"Isola","year":"2010","journal-title":"Breast cancer research"},{"key":"56","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/modpathol.3800459","article-title":"Expression of heat-shock protein-90 in non-Hodgkin's lymphomas","volume":"18","author":"Medeiros","year":"2005","journal-title":"Mod Pathol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T13:57:20Z","timestamp":1596722240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,16]]},"references-count":56,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2017,4,18]]}},"alternative-id":["15410","28412732"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.15410","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,16]]}}}